Research update – ProQR
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
Search results
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
Jing Yu is a bioinformatician with the Eye Research Group at Oxford University, and is part of the UK Inherited Retinal Dystrophy Consortium (UKIRDC) team, funded by a Retina UK grant.
A huge thank you to everyone who completed our 2025 sight loss survey. This year we received over 600 responses. It follows similar surveys in 2019 and 2022 which led directly to the introduction of our Unlock Genetics and Discover Wellbeing resources, as well as shaping our work with the professional community who support people with inherited sight loss.
Thank you to all those who completed our recent Sight Loss Survey – almost 700 of you took the time to share your experiences.
Tribute to Retina UK founder Lynda Cantor MBE
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Saturday 25 July, 12.00pm - 4.00pm - In-person - Please come and join facilitator Perm Bhachu and the group for their latest in-person social catch up over lunch at The Old House at Home pub in Harborne.
Whether you are looking for practical information or emotional support, online, by phone or face-to-face, we’re here to help.
The clinical trial team at The Retina Clinic London have asked us to share an opportunity to participate in a Phase 1 clinical trial for AAVB 039 for Stargardt Disease.
Our community is informed and knowledgeable about current research projects into the cause(s) of and treatments for these conditions.